These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17363538)

  • 1. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
    Talbot DC; von Pawel J; Cattell E; Yule SM; Johnston C; Zandvliet AS; Huitema AD; Norbury CJ; Ellis P; Bosquee L; Reck M
    Clin Cancer Res; 2007 Mar; 13(6):1816-22. PubMed ID: 17363538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
    Zandvliet AS; Schellens JH; Dittrich C; Wanders J; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2008 Oct; 66(4):485-97. PubMed ID: 18637887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
    Dittrich C; Zandvliet AS; Gneist M; Huitema AD; King AA; Wanders J
    Br J Cancer; 2007 Feb; 96(4):559-66. PubMed ID: 17285128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
    van Kesteren C; Zandvliet AS; Karlsson MO; Mathôt RA; Punt CJ; Armand JP; Raymond E; Huitema AD; Dittrich C; Dumez H; Roché HH; Droz JP; Ravic M; Yule SM; Wanders J; Beijnen JH; Fumoleau P; Schellens JH
    Invest New Drugs; 2005 Jun; 23(3):225-34. PubMed ID: 15868378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
    Siegel-Lakhai WS; Zandvliet AS; Huitema AD; Tibben MM; Milano G; Girre V; Diéras V; King A; Richmond E; Wanders J; Beijnen JH; Schellens JH
    Br J Cancer; 2008 Apr; 98(8):1320-6. PubMed ID: 18414469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
    Zandvliet AS; Siegel-Lakhai WS; Beijnen JH; Copalu W; Etienne-Grimaldi MC; Milano G; Schellens JH; Huitema AD
    Clin Pharmacol Ther; 2008 Jun; 83(6):829-39. PubMed ID: 17851564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
    Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):543-70. PubMed ID: 16946998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
    Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
    Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
    Punt CJ; Fumoleau P; van de Walle B; Faber MN; Ravic M; Campone M
    Ann Oncol; 2001 Sep; 12(9):1289-93. PubMed ID: 11697842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
    Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
    J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):39-62. PubMed ID: 19199010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
    Ozawa Y; Kusano K; Owa T; Yokoi A; Asada M; Yoshimatsu K
    Cancer Chemother Pharmacol; 2012 May; 69(5):1353-62. PubMed ID: 22349812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
    Mauer AM; Cohen EE; Ma PC; Kozloff MF; Schwartzberg L; Coates AI; Qian J; Hagey AE; Gordon GB
    J Thorac Oncol; 2008 Jun; 3(6):631-6. PubMed ID: 18520803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.
    Rudin CM; Mauer A; Smakal M; Juergens R; Spelda S; Wertheim M; Coates A; McKeegan E; Ansell P; Zhou X; Qian J; Pradhan R; Dowell B; Krivoshik A; Gordon G
    J Clin Oncol; 2011 Mar; 29(8):1075-82. PubMed ID: 21300929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
    Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
    Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.